Recurrent Melanoma Terminated Phase 1 Trials for Ipilimumab (DB06186)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00039091Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTreatment